UK & Ireland, experts provided insights on market trends within the clinical trial industry and advice on engagement ...

The first quarter of 2025 saw a wave of significant advancements in clinical research across oncology, neurology, dermatology, respiratory, and rare diseases.

The REPORT guide is a ‘How to’ guide to help you report your clinical research in an effective and transparent way. It is intended to supplement established first choice reporting tools, such as ...

Whether antiretroviral therapy (ART) is always completely suppressive, or HIV might continue to replicate at low levels despite ART in some people with HIV (PWH), is still debated. Here, we ...

After 2024, which saw a steady recovery by the life sciences industry, it looks like 2025 is set to be a year of change and development, particularly in clinical trials. The good news is that ...

Introduction Adolescent idiopathic scoliosis (AIS) often imposes a significant psychological burden on teenagers. Cognitive and behavioural strategies have demonstrated the potential to alleviate ...

In many cases, we’ve simply layered new tools onto an outdated operating model. The structure beneath—the way clinical trials ...

Recently, alternative endpoints, including progression-free survival (PFS), have emerged as popular readouts for many phase 3 clinical trials. PFS indicates the time from diagnosis (or treatment ...

China’s NMPA is proposing to cut down the clinical trial review waiting period for novel medicines to 30 working days from the current 60.

Karen Peterson was diagnosed with stage 1 triple-negative breast cancer that quickly returned as stage 4. Joining a clinical ...